Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open ...
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b clinical study results concluded continuous low dose …